Northern Tool + Equipment Teams up with Monster Jam® to bring Legendary Truck to New Orleans
The store event includes an exclusive deal for New Orleans-area customers to receive two free Monster Jam® event tickets NEW ORLEANS, Feb. 10, 2026 /PRNewswire/... Read more.
CIBO’s Data and Analytics Platform Helps Power Nutrien’s Sustainable Agriculture Programs
MINNEAPOLIS, Feb. 10, 2026 /PRNewswire/ — CIBO Technologies, the leading independent data and analytics platform for agriculture, today announced a strategic... Read more.
/C O R R E C T I O N — CIBO Technologies, Inc./
In the news release, CIBO’s Data and Analytics Platform Helps Power Nutrien’s Sustainable Agriculture Programs, issued 10-Feb-2026 by CIBO Technologies,... Read more.
Atmosphere Data Centers Appoints Chris Baughman as Chief Platform and Sustainability Officer
NEWPORT BEACH, Calif., Feb. 10, 2026 /PRNewswire/ — Atmosphere Data Centers announces the appointment of Chris Baughman as Chief Platform and Sustainability... Read more.
ADP National Employment Report Preliminary Estimate for January 24, 2026
ROSELAND, N.J., Feb. 10, 2026 /PRNewswire/ — For the four weeks ending January 24, 2026, U.S. private employers added an average of 6,500 jobs per week, according... Read more.
MEDIA ADVISORY – MDA SPACE TO HOLD ITS FOURTH QUARTER 2025 EARNINGS CONFERENCE CALL ON MARCH 4, 2026
BRAMPTON, ON, Feb. 10, 2026 /PRNewswire/ – MDA Space Ltd. (TSX: MDA), a trusted mission partner to the rapidly expanding global space industry, will release... Read more.
100 Reasons to Celebrate: IXL Honors the Teachers Powering Today’s Classrooms
IXL’s Elite 100 recognizes educators who went the extra mile to help their students succeed SAN MATEO, Calif., Feb. 10, 2026 /PRNewswire/ — Teachers... Read more.
ZINZINO AB (PUBL.): ZINZINO ANNOUNCES PERU AS NEXT STEP IN ITS GLOBAL EXPANSION
GOTHENBURG, Sweden, Feb. 10, 2026 /PRNewswire/ — Zinzino is pleased to announce that it will launch its operations in Peru on February 10th, 2026. Zinzino... Read more.
Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, in Relapsed/Refractory Osteosarcoma
Tegavivint Is the First Wnt/β-Catenin Inhibitor to Demonstrate Tolerability and Monotherapy Clinical Activity in Complex Solid Tumors Osteosarcoma Program Builds... Read more.
On Site: “2026 China Forum on Source Innovation in New Drug Discovery” Concludes Successfully
SHANGHAI, Feb. 10, 2026 /PRNewswire/ — As China’s new drug R&D enters the “deep waters” of homogeneous competition, the path for followers... Read more.